Immunomedics Inc. (IMMU1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
CEO:
David M. Goldenberg
Employees:
185
300 AMERICAN RD, MORRIS PLAINS, NJ 07950
9736058200

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. The company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It markets and sells its products in the U.S. and throughout Europe. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.

Data derived from most recent annual or quarterly report
Market Cap 20.309 Billion Shares Outstanding231.157 Million Avg 30-day Volume 4.7 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.74
Price to Revenue402.1664 Debt to Equity0.0 EBITDA-308.786 Million
Price to Book Value13.8066 Operating Margin-1536.6586 Enterprise Value7.215 Billion
Current Ratio12.841 EPS Growth-0.042 Quick Ratio12.279
1 Yr BETA 1.878 52-week High/Low 0.0 / Profit Margin-1735.6669
Operating Cash Flow Growth-88.5418 Altman Z-Score8.3575 Free Cash Flow to Firm -113.307 Million
View SEC Filings from IMMU1 instead.

View recent insider trading info

Funds Holding IMMU1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IMMU1

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2020-10-23:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-09-21:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-09-17:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2020-09-14:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-17:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-07-06:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-05-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-05-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-04-22:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Proxy

    Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ITRI LORETTTA M CHIEF MEDICAL OFFICER

    • Officer
    No longer subject to file 2020-10-23 0

    HUTT PETER BARTON

    • Director
    No longer subject to file 2020-10-23 0

    CANUTE SCOTT A

    • Director
    No longer subject to file 2020-10-23 0

    DUNCAN BARBARA GAYLE

    • Director
    No longer subject to file 2020-10-23 0

    BAUM CHARLES M

    • Director
    No longer subject to file 2020-10-23 0

    AGHAZADEH BEHZAD

    AVORO CAPITAL ADVISORS LLC

    • Director
    • 10% Owner
    • SEE REMARKSSEE REMARKS
    No longer subject to file 2020-10-23 0

    ANDREWS KURT J. CHIEF HUMAN RESOURCES OFFICER

    • Officer
    No longer subject to file 2020-10-23 0

    AZELBY ROBERT

    • Director
    No longer subject to file 2020-10-23 0

    ISLAM KHALID

    • Director
    No longer subject to file 2020-10-23 0

    DELANEY BRENDAN CHIEF COMMERCIAL OFFICER

    • Officer
    No longer subject to file 2020-10-23 0

    MALIK USAMA CHIEF FIN. & BUSINESS OFFICER

    • Officer
    No longer subject to file 2020-10-23 0

    FRICKER WILLIAM PRINCIPAL ACCOUNTING OFFICER

    • Officer
    No longer subject to file 2020-10-23 0

    FREEDBERG JARED GEN. COUNSEL & CORP. SECRETARY

    • Officer
    No longer subject to file 2020-10-23 0

    BALL BRYAN CHIEF QUALITY OFFICER

    • Officer
    No longer subject to file 2020-10-23 0

    SEMERJIAN HAROUT PRESIDENT AND CEO

    • Officer
    • Director
    50,075 2020-04-16 0

    ROSENBERG MORRIS CHIEF TECHNOLOGY OFFICER

    • Officer
    0 2019-09-06 0

    IANNONE ROBERT CHIEF MEDICAL OFFICER

    • Officer
    0 2019-03-14 0

    PEHL MICHAEL F. PRESIDENT AND CEO

    • Officer
    0 2018-09-14 0

    GOLDENBERG DAVID M

    • Director
    7,387,537 2018-02-28 0

    MARKISON BRIAN A

    • Director
    90,788 2017-11-20 0

    VENBIO SELECT ADVISOR LLC

    • Director
    • 10% Owner
    • SEE REMARKS
    16,064,461 2017-11-14 0

    AGHAZADEH BEHZAD

    • Director
    • 10% Owner
    • SEE REMARKS
    16,064,461 2017-11-14 0

    GOLDENBERG CYNTHIA L

    • Director
    5,906,233 2017-08-31 0

    GARONE MICHAEL CHIEF FINANCIAL OFFICER

    • Officer
    0 2017-07-03 0

    STARK DON C

    • Director
    No longer subject to file 2017-06-30 0

    COX GEOFFREY F

    • Director
    0 2017-01-08 0

    FORRESTER ROBERT

    • Director
    0 2017-01-08 0

    ARYEH JASON

    • Director
    0 2017-01-08 0

    OLIVER BOB

    • Director
    0 2017-01-08 0

    PAETZOLD MARY E

    • Director
    78,325 2016-12-02 0

    KIRSCH ARTHUR S

    • Director
    0 2015-12-02 0

    SHERMAN RICHARD L.

    • Director
    No longer subject to file 2015-12-01 0

    PFREUNDSCHUH PETER P. CHIEF FINANCIAL OFFICER

    • Officer
    29,706 2015-08-20 0

    COLEMAN MORTON

    • Director
    No longer subject to file 2013-12-04 0

    LOCASTRO MARCELLA

    • Director
    No longer subject to file 2013-12-04 0

    GORMAN GERARD G SVP, FIN. , AND CFO

    • Officer
    0 2013-08-16 0

    ZUERBLIS KENNETH J

    • Director
    9,167 2011-12-07 0

    WOLYNIC EDWARD T

    • Director
    6,667 2009-12-02 0

    JAFFE MARVIN

    • Director
    15,000 2006-08-24 0

    PIVIROTTO RICHARD R

    • Director
    25,000 2006-08-24 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    American Century Quantitative Equity Funds, Inc.- AC Alternatives Equity Market Neutral Fund IMMU1 -4999.0 shares, $-105778.84 2019-12-31 N-PORT
    American Century Quantitative Equity Funds, Inc.- AC Alternatives Disciplined Long Short Fund IMMU1 -4122.0 shares, $-87221.52 2019-12-31 N-PORT
    American Century Quantitative Equity Funds, Inc.- Core Equity Plus Fund IMMU1 -27324.0 shares, $-362316.24 2019-09-30 N-PORT
    AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund IMMU1 -73.0 shares, $-6207.19 2020-09-30 N-PORT
    American Century Quantitative Equity Funds, Inc.- NT Core Equity Plus Fund IMMU1 -83315.0 shares, $-1104756.9 2019-09-30 N-PORT
    Trust for Professional Managers- Convergence Market Neutral Fund IMMU1 -1592.0 shares, $-70939.52 2020-08-31 N-PORT
    AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund IMMU1 -50.0 shares, $-663.0 2019-09-30 N-PORT

    Elevate your investments